Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2018 2
2021 6
2022 4
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Laloi L, Billotey NC, Dumas PY, Paul F, Villate A, Simand C, Fornecker L, Puisset F, Bertoli S, Simonet MB, Laribi K, Houyou D, Santagostino A, Michel C, Guepin GR, Guerineau E, Tabrizi R, Hunault M, Giltat A, Kaphan E, Bulabois C, Cartet E, Rocher C, Lachenal F, Morisset S, Récher C, Pigneux A, Belhabri A, Michallet M, Michallet AS. Laloi L, et al. Among authors: giltat a. Cancer Med. 2023 Mar;12(6):7175-7181. doi: 10.1002/cam4.5459. Epub 2022 Dec 8. Cancer Med. 2023. PMID: 36482507 Free PMC article.
Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores.
Bachelot A, Bouvier A, Riou J, Thepot S, Giltat A, Nunes Gomes C, Paillassa J, Jouanneau-Courville R, Renard M, Beucher A, Cottin L, Wiber M, Ribourtout B, Geneviève F, Luque Paz D, Tanguy-Schmidt A, Ugo V, Hunault-Berger M, Blanchet O, Orvain C. Bachelot A, et al. Among authors: giltat a. Am J Hematol. 2023 Jun;98(6):922-931. doi: 10.1002/ajh.26917. Epub 2023 Apr 5. Am J Hematol. 2023. PMID: 36964937
Implementation of a new blood cultures sampling strategy in patients receiving intensive chemotherapy for acute leukemia and/or hematopoietic cell transplantation.
Declerck C, Giltat A, Boutemy R, Brisset-Dheilly M, Pelhatre A, Hunault-Berger M, Kempf M, Kouatchet A, Mahieu R, Tanguy-Schmidt A, Orvain C. Declerck C, et al. Among authors: giltat a. Leuk Lymphoma. 2023 Jun;64(6):1204-1207. doi: 10.1080/10428194.2023.2196595. Epub 2023 Apr 13. Leuk Lymphoma. 2023. PMID: 37052331 No abstract available.
Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide.
Jullien M, Orvain C, Berceanu A, Couturier MA, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, Hunault M, Daguindau E, Roussel X, Delepine P, Guillerm G, Giltat A, François S, Thepot S, Le Gouill S, Béné MC, Chevallier P. Jullien M, et al. Among authors: giltat a. Cancer Med. 2021 Oct;10(20):7194-7202. doi: 10.1002/cam4.4262. Epub 2021 Sep 21. Cancer Med. 2021. PMID: 34547182 Free PMC article.
Toxicity Profile According to Etoposide and Cytarabine Dosing in Patients with Lymphoma Receiving Autologous Stem Cell Transplantation Following BEAM Conditioning.
Vely A, Paillassa J, Nunes Gomes C, Giltat A, Fouquet S, Lebreton A, Klemencie M, Clavert A, Tanguy-Schmidt A, Hunault-Berger M, Orvain C. Vely A, et al. Among authors: giltat a. Ann Hematol. 2023 Aug;102(8):2225-2231. doi: 10.1007/s00277-023-05333-z. Epub 2023 Jun 28. Ann Hematol. 2023. PMID: 37380715
Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial.
Drevin G, Briet M, Bazzoli C, Gyan E, Schmidt A, Dombret H, Orvain C, Giltat A, Recher C, Ifrah N, Guardiola P, Hunault-Berger M, Abbara C. Drevin G, et al. Among authors: giltat a. Pharmaceutics. 2022 Apr 5;14(4):792. doi: 10.3390/pharmaceutics14040792. Pharmaceutics. 2022. PMID: 35456626 Free PMC article.
Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome.
Guillaume T, Thépot S, Peterlin P, Ceballos P, Bourgeois AL, Garnier A, Orvain C, Giltat A, François S, Bris YL, Fronteau C, Planche L, Chevallier P. Guillaume T, et al. Among authors: giltat a. Transplant Cell Ther. 2021 Oct;27(10):839.e1-839.e6. doi: 10.1016/j.jtct.2021.06.029. Epub 2021 Jul 3. Transplant Cell Ther. 2021. PMID: 34224913 Free article.
17 results